Prime Medicine Inc (NASDAQ:PRME) has a beta value of 1.87 and has seen 2.89 million shares traded in the last trading session. The PRME stock price is -315.58% off its 52-week high price of $8.27 and 17.09% above the 52-week low of $1.65. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.53 million shares traded. The 3-month trading volume is 1.14 million shares.
The consensus among analysts is that Prime Medicine Inc (PRME) is Buy stock at the moment, with a recommendation rating of 1.18. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.31.
Prime Medicine Inc (NASDAQ:PRME) trade information
Over the past 30 days, the shares of Prime Medicine Inc (NASDAQ:PRME) have changed -21.03%. Short interest in the company has seen 19.41 million shares shorted with days to cover at 14.73.
Wall Street analysts have a consensus price target for the stock at $17, which means that the shares’ value could jump 88.29% from current levels. The projected low price target is $12.0 while the price target rests at a high of $23.0. In that case, then, we find that the current price level is -1055.78% off the targeted high while a plunge would see the stock gain -503.02% from current levels.
Prime Medicine Inc (PRME) estimates and forecasts
The company’s shares have lost -44.10% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 560.21%.
9 analysts offering their estimates for the company have set an average revenue estimate of 3.43M for the current quarter. 9 have an estimated revenue figure of 3.39M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -124.13% over the past 5 years. Earnings growth for 2025 is a modest 27.26% while over the next 5 years, the company’s earnings are expected to increase by 12.59%.
PRME Dividends
Prime Medicine Inc is expected to release its next earnings report on 2025-Feb-27 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Prime Medicine Inc (NASDAQ:PRME)’s Major holders
Insiders own 23.91% of the company shares, while shares held by institutions stand at 59.07% with a share float percentage of 77.63%. Investors are also buoyed by the number of investors in a company, with Prime Medicine Inc having a total of 172.0 institutions that hold shares in the company. The top two institutional holders are ALPHABET INC. with over 15.06 million shares worth more than $77.42 million. As of 2024-06-30, ALPHABET INC. held 12.6375% of shares outstanding.
The other major institutional holder is ARK INVESTMENT MANAGEMENT LLC, with the holding of over 6.13 million shares as of 2024-06-30. The firm’s total holdings are worth over $31.49 million and represent 5.1404% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Trust-ARK Genomic Revolution ETF and ARK ETF Trust-ARK Innovation ETF . As of Feb 28, 2025 , the former fund manager holds about 1.98% shares in the company for having 2.59 shares of worth $5.16 million while later fund manager owns 2.17 shares of worth $4.33 million as of Feb 28, 2025 , which makes it owner of about 1.66% of company’s outstanding stock.
